Syngene International Limited
₹402.60+₹4.30 (+1.1%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹25,375 Cr
- P/E
- 58.0x
- EV / EBITDA
- 26.5x
- Revenue
- ₹3,373 Cr
- Net margin
- 14.5%
- ROCE
- 19.5%
Price chart
Technical chartScreen technicals →-38.1% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +10.4%
- 3M
- +0.9%
- 6M
- -14.0%
- 1Y
- -38.1%
- 5Y
- -27.1%
52-week range
Day change +₹4.30 (+1.1%) from ₹398 to ₹403 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in SYNGENE, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Operating margin of 27.5% exceeds Healthcare median (24.8%)
Concerns1
- Operating margin declining for 3 consecutive years (29.0% → 28.0% → 27.0%)
Rule-based from financial data. Not advice.
About the company
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally.
Read moreShow less
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
- Sector
- Healthcare
- Shares outstanding
- 40.3 Cr shares
- ISIN
- INE398R01022
- BSE code
- 539268
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹25,375 Cr
- P/E
- 58.0x
- P/B
- 5.5x
- EV / EBITDA
- 26.5x
- EV / Sales
- 7.9x
- P/S
- 7.9x
- Earnings yield
- 1.7%
- 52-week high
- ₹663.65
- 52-week low
- ₹345.70
Profitability
- Operating margin
- 27.5%
- Net margin
- 14.5%
- EBITDA margin
- 29.8%
- ROE
- 11.1%
- ROCE
- 19.5%
- ROA
- 8.0%
- Dividend payout
- 11.0%
- Tax rate
- 16.0%
- Other income, % of PBT
- 13.3%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹3,373 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 5.3%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 9.7%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹955 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -5.0%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 0.4%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 2.5%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹913 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.9%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹167 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -0.2%
Solvency and efficiency
- Current ratio
- 2.10
- Debt / Equity
- 0.08
- Debt / Assets
- 0.06
- Debt / EBITDA
- 0.35
- Interest coverage
- 29.37
- Financial leverage
- 1.39
- CFO / Net profit
- 1.96
- Cash / Market cap
- 7.2%
- Cash per share
- ₹45.41
- Asset turnover
- 0.55
- Fixed asset turnover
- 1.38
- Capital intensity
- 0.72
- Debtor days
- 49 days
- Inventory turnover
- 3.84
- Cash conversion cycle
- 41 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹14 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹2,453 Cr |
| Sales | Operating profit | ₹920 Cr |
| Operating profit | Interest | ₹31 Cr |
| Operating profit | Depreciation | ₹367 Cr |
| Operating profit | Profit before tax | ₹522 Cr |
| Other income | Profit before tax | ₹100 Cr |
| Profit before tax | Tax and other | ₹154 Cr |
| Profit before tax | Net profit | ₹468 Cr |
Revenue and net profit
Revenue grew 5.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹2,179 Cr | ₹404 Cr |
| FY2022 | ₹2,601 Cr | ₹394 Cr |
| FY2023 | ₹3,194 Cr | ₹473 Cr |
| FY2024 | ₹3,203 Cr | ₹466 Cr |
| FY2025 | ₹3,373 Cr | ₹468 Cr |
Cash flows
FY2025: ₹1,114 Cr from operations, ₹304 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹698 Cr | ₹69 Cr |
| FY2022 | ₹582 Cr | -₹29 Cr |
| FY2023 | ₹838 Cr | ₹153 Cr |
| FY2024 | ₹913 Cr | ₹530 Cr |
| FY2025 | ₹1,114 Cr | ₹304 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹3,373 Cr+5.3%1Y
- Net profit
- ₹468 Cr+0.4%1Y
- Cash from operations
- ₹1,114 Cr
- Free cash flow
- ₹304 Cr-42.6%1Y
- Revenue CAGR, 5Y
- 9.7%
- EBITDA CAGR, 5Y
- 4.4%
- Net profit CAGR, 5Y
- 2.5%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹3,373 Cr | ₹920 Cr | — | ₹468 Cr | ₹1,114 Cr | ₹304 Cr | 10.1% | +5.3% | +0.4% |
Monthly returns
Month-by-month returns of SYNGENE across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹6,407 Cr |
| Equity capital | ₹402 Cr |
| Reserves | ₹4,236 Cr |
| Borrowings | ₹306 Cr |
| Other liabilities | ₹1,462 Cr |
| Assets | ₹6,407 Cr |
| Fixed assets | ₹2,241 Cr |
| Capital work in progress | ₹880 Cr |
| Investments | ₹1,468 Cr |
| Other assets | ₹1,818 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
SYNGENE trades at 58.0x earnings against a peer median of 52.6x (a 10% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Syngene International LimitedSYNGENEthis companyP/E ↑ premium | ₹25,375 Cr | 58.0x | 5.5x | 11.1% | 26.5x |
| J.B. Chemicals & Pharmaceuticals LtJBCHEPHARM | ₹29,217 Cr | 41.5x | 7.9x | 18.8% | 32.1x |
| Gland Pharma LimitedGLAND | ₹28,321 Cr | 24.5x | 2.8x | 11.6% | 17.3x |
| Krishna Institute of Medical Sciences LimitedKIMS | ₹24,919 Cr | 87.7x | 10.9x | 12.6% | 65.6x |
| Pine Labs LimitedPINELABS | ₹24,711 Cr | 442.0x | — | -9.1% | 164.0x |
| Dr. Lal Pathlabs LimitedLALPATHLAB | ₹23,777 Cr | 45.0x | 10.2x | 20.2% | 38.3x |
| Wockhardt LtdWOCKPHARMA | ₹22,539 Cr | 160.0x | 7.8x | -23.5% | -2690.8x |
| PIRAMAL PHARMA LIMITEDPPLPHARMA | ₹22,363 Cr | 31.7x | 2.9x | 5.8% | 27.6x |
| Pfizer Ltd.PFIZER | ₹22,230 Cr | 31.5x | 5.8x | 15.3% | 26.2x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
SYNGENE since 1 January, against earlier years.
Historical volatility
SYNGENE's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 31.0% |
| FY2022 | 28.0% |
| FY2023 | 29.0% |
| FY2024 | 28.0% |
| FY2025 | 27.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹3,373 Cr |
| Costs | |
| Interest | ₹31 Cr |
| Expenses | ₹2,453 Cr |
| Operating profitOperating Profit | ₹920 Cr |
| Other income and charges | |
| Profit before tax | ₹622 Cr |
| Tax | |
| Net profitNet Profit | ₹468 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹6,407 Cr |
| Equity capitalEquity Capital | ₹402 Cr |
| Reserves | ₹4,236 Cr |
| Borrowings | ₹306 Cr |
| Other liabilitiesOther Liabilities | ₹1,462 Cr |
| AssetsTotal Assets | ₹6,407 Cr |
| Fixed assetsFixed Assets | ₹2,241 Cr |
| Capital work in progressCWIP | ₹880 Cr |
| Investments | ₹1,468 Cr |
| Other assetsOther Assets | ₹1,818 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹1,114 Cr |
| Investing cash flowCash from Investing Activity | -₹810 Cr |
| Financing cash flowCash from Financing Activity | -₹136 Cr |
| Change in cashNet Cash Flow | ₹167 Cr |
Learn while you research
Academy chapters picked for Syngene International Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 58.0, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read